HeartBeam Partners with European Consortium to Test At-Home ECG for High-Risk Cardiac Patients

  • HeartBeam joins the EXIT-CVD research consortium led by UMCG and Philips to advance at-home ECG monitoring for high-risk cardiac patients.
  • The HEART-CHECK study will evaluate HeartBeam’s system for early detection of acute coronary syndrome (ACS) in post-discharge patients.
  • HeartBeam’s contribution is in-kind, including devices and clinical team expertise, with the study designed as a hybrid effectiveness-implementation trial.
  • EXIT-CVD aims to transform cardiovascular disease detection and treatment through 22 clinical studies involving 14,000+ patients across Europe.
  • HeartBeam’s system received FDA Breakthrough Device Designation for heart attack assessment at home, though its use remains investigational.

HeartBeam’s partnership in the EXIT-CVD consortium aligns with the broader shift toward decentralized, at-home healthcare solutions. The project’s focus on early detection and remote monitoring reflects growing investment in preventive cardiac care, particularly for high-risk patients. With 42 partners across 17 countries and a €27.6 million budget, EXIT-CVD represents a significant collaborative effort to transform cardiovascular disease management in Europe.

Regulatory Progress
Whether HeartBeam can secure FDA clearance for heart attack assessment, expanding its system’s use beyond arrhythmia detection.
Clinical Validation
The effectiveness of the HEART-CHECK study in demonstrating the HeartBeam System’s ability to reduce hospital readmissions and improve care for high-risk patients.
Market Expansion
The pace at which HeartBeam can leverage the EXIT-CVD consortium to enter European markets and compete with established cardiac monitoring solutions.